Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Biopharma Licenses Sustained Release Technology to Gilead for HIV Product
News Update

Share on Stocktwits


The two California-based companies will collaborate on specific related development activities.

DURECT Corp. (DRRX:NASDAQ) announced in a news release it entered an agreement regarding its SABER technology with Gilead Sciences. SABER provides sustained release for long-acting injectable products.

DURECT grants Gilead the exclusive global rights to use SABER in developing and commercializing a long-acting, injectable human immunodeficiency virus (HIV) product. DURECT also affords Gilead access to the SABER platform for HIV and the hepatitis B virus (HBV) and the exclusive option to license additional SABER-based products targeting those indications.

"We've been working together on this program as a feasibility project, and are now delighted that Gilead has chosen to advance this effort into a formal development program," DURECT President and CEO James E. Brown said in the release.

In exchange, Gilead will pay DURECT $25 million upfront, along with potentially up to an additional $75 million in development and regulatory milestones and up to an another $70 million in sales-based milestones and tiered royalties on product sales. For exclusive licensing of other SABER-based products aimed at HIV and HBV, Gilead would pay $150 apiece in upfront, development, regulatory and sales-based milestones as well as tiered royalties on sales.

"The parties will collaborate on specified development activities with Gilead controlling and funding the development programs," the release noted.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: DURECT Corp. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe